Pazopanib - GlaxoSmithKline/Novartis

Drug Profile

Pazopanib - GlaxoSmithKline/Novartis

Alternative Names: 786034; Armala; GW-786034; GW-786034B; Pazopanib hydrochloride; SB-786034; Votrient

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer Duke University Medical Center; GlaxoSmithKline; Masonic Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; SCRI Development Innovations; University of Minnesota; University of Oxford; University of Washington
  • Class Antineoplastics; Indazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein b raf inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma; Sarcoma
  • Phase II Acute myeloid leukaemia; Bladder cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Endometrial cancer; Fallopian tube cancer; Gallbladder cancer; Gastrointestinal stromal tumours; Glioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Thyroid cancer; Urogenital cancer
  • Phase I/II Malignant melanoma
  • No development reported Colorectal cancer; Hepatocellular carcinoma; Prostate cancer
  • Discontinued Age-related macular degeneration; Hereditary haemorrhagic telangiectasia; Inflammatory breast cancer

Most Recent Events

  • 10 Jan 2018 GlaxoSmithKline withdraws a phase II trial prior to enrolment in Breast cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA and Germany (PO) (NCT00615524)
  • 30 Nov 2017 Phase-II clinical trials in Renal cell carcinoma (Late-stage disease, Second-line therapy or greater) in Hungary, Austria, Germany, Spain, Czech Republic (PO) (NCT03200717) (EudraCT2017-000708-10)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy) in European Union (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top